ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SBIO ALPS Medical Breakthroughs ETF

盘后交易 11-05 18:41:44 EST

52.83

-2.98

-5.34%

盘后52.83

+0.000.00%

16:10 EST

最高55.96	最低52.83	成交量2.04万
今开55.96	昨收55.81	日振幅5.61%
总市值1.77亿	流通市值1.77亿	总股本335.00万
成交额109.41万	换手率0.61%	流通股本335.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":52.83,"timestamp":1793912400000,"preClose":55.81,"halted":0,"volume":20394,"hourTrading":{"tag":"盘后","latestPrice":52.83,"preClose":52.83,"latestTime":"16:10 EST","volume":9,"amount":475.46999999999997,"timestamp":1793913005248,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05339544884429321,"floatShares":3350000,"shares":3350000,"eps":0,"marketStatus":"盘后交易","change":-2.98,"latestTime":"11-05 18:41:44 EST","open":55.96,"high":55.96,"low":52.83,"amount":1094084,"amplitude":0.056083,"askPrice":71.96,"askSize":100,"bidPrice":50.14,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793926800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":55.81,"sharesOutstanding":2675000,"nav":55.81,"aum":186971402.35,"bidAskSpread":0.002441,"postHourTrading":{"tag":"盘后","latestPrice":52.83,"preClose":52.83,"latestTime":"16:10 EST","volume":9,"amount":475.46999999999997,"timestamp":1793913005248,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.069126,"impliedVol":0.2672,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/SBIO","defaultTab":"news","newsList":[{"id":"2680408087","title":"悦康药业：拟变更部分募投项目投向创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2680408087","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680408087?lang=zh_cn&edition=full","pubTime":"2026-11-04 15:41","pubTimestamp":1793778066,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["APXH","SBIO","IBB","GSKH","BK4588","BK4585","BIOY","PBE","GDOC","XLVI","WRND","LFSC","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678643331","title":"DeLLphi-305 Ⅲ期临床试验结果显示：英飞凡联合安泰适一线治疗广泛期小细胞肺癌，将死亡风险降低58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678643331","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678643331?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:47","pubTimestamp":1793008020,"startTime":"0","endTime":"0","summary":"联合治疗组约有79%的患者在一年时仍存活，而单药组这一比例为53%。联合治疗组的中位PFS为7.4个月，而单药组为1.9个月。联合方案治疗导致的治疗终止发生率较低，且未发生与治疗相关的死亡事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5080617_ZH80617_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5080617_ZH80617_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AZNH","PJP","LU2322448791.USD","IYH","MEDI","LU2237443382.USD","XBIX","MRNX","IDNA","LU0708994859.HKD","BBH","FBT","LFSC","LU1992135472.HKD","LU2237443549.SGD","LU2417539215.USD","BK4007","TMED","BIB","MRNY","LU0128525929.USD","SYNB","BME","SBIO","IEIH","RSPH","LU2272731865.HKD","LU1992135399.USD","PPH","GNOM","AZN","IBRN","IBB","FTXH","RXL","BIOY","IE00B5TLWC47.USD","PBE","LU2237443465.HKD","XPH","LU0889565916.HKD","WDNA","CANC","LU2089984988.USD","BBP","PSCH","PBPH","IEHS","HELX","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676639504","title":"DISC MEDICINE INC.股价飙升41%，此前该公司公布了BITOPERTIN三期临床试验结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2676639504","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676639504?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:30","pubTimestamp":1792402213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","MRNX","TMED","IYH","MRNY","CANC","IEHS","XPH","LU1992135399.USD","LU2322448957.HKD","WDNA","LU2272731600.USD","BBH","IE00B5TLWC47.USD","PPH","HELX","BIB","SBIO","LU2272731782.SGD","BK4585","LFSC","AZNH","RSPH","SYNB","BME","IDNA","XBIX","IEIH","IBRN","FBT","RXL","PSCH","FTXH","PJP","PBE","BIOY","BK4588","LU2272731865.HKD","PBPH","MEDI","LU2322448791.USD","LU1992135472.HKD","LU2473716301.USD","IBB","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673501811","title":"科创板集成电路、创新药研发成果进入实质兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2673501811","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673501811?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:56","pubTimestamp":1791374163,"startTime":"0","endTime":"0","summary":"近期，科创板公司研发频传利好消息，从创新药的首例入组和新适应证获批，到集成电路的存储平台量产与核心芯片交付，越来越多成果转化为实实在在的创新产出，科创板硬科技企业正从“持续投入”走向“成果兑现”。集成电路板块多点突破，存储、端侧AI、模拟与车规芯片均有实质进展落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610073888922323.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610073888922323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","PBE","GDOC","LFSC","WRND","IBB","BK4588","XLVI","BBP","KSTR","APXH","159546","BK4585","SBIO","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114208?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSCH","BIOY","IE00B4R5TH58.HKD","FBT","IBB","CANC","PPH","TMED","AMGN","PJP","IEHS","AZNH","BIB","TBXU","LU0109394709.USD","RXL","PBE","BBP","LU1992135472.HKD","XPH","SYNB","FTXH","WDNA","IYH","IBRN","BK4599","BK4585","BBH","LU0320765992.SGD","MEDI","MRNX","RSPH","LU2473716301.USD","PBPH","LU2272731865.HKD","LU0122379950.USD","GNOM","HELX","LFSC","SBIO","LU0058720904.USD","BME","XBIX","MRNY","IE00B5TLWC47.USD","LU2242646821.SGD","IDNA","LU2272731782.SGD","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669169682?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["SBIO","BIOY","BK0251","BK0070","SETM","XLVI","BK4588","GSKH","BK0188","BK0155","IBB","GDOC","LFSC","PBE","APXH","WRND","BK0216","600721","BBP","600499","BK4585","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669137049?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","XLVI","BK4588","LFSC","APXH","06978","BK1161","PBE","GSKH","159992","BBP","BK4585","WRND","LNGR","SBIO","IBB","GDOC","IBBQ","BIOY","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668946461","title":"Xenon制药美股盘前跌超28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668946461","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668946461?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:09","pubTimestamp":1789718975,"startTime":"0","endTime":"0","summary":"【Xenon制药美股盘前跌超28%】Xenon制药美股盘前跌超28%，因公司暂停了抑郁症药物试验的新患者招募。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878613718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878613718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106034976","title":"Xenon制药盘前股价暴跌27.5%，因暂停抑郁症药物试验新患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1106034976","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106034976?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:06","pubTimestamp":1789718769,"startTime":"0","endTime":"0","summary":"Xenon制药（Xenon Pharmaceuticals）盘前交易中股价大幅下挫，跌幅高达27.5%。这一剧烈波动源于该公司宣布，已决定暂停其抑郁症药物试验的新患者招募工作。市场对此消息反应迅速且激烈，投资者信心受到明显冲击。此举意味着，这家生物制药公司在推进其核心候选药物临床研发进程中，遭遇了意料之外的阻碍。尽管公司方面尚未透露暂停的具体原因，但资本市场已用脚投票，显示出对这一变数的深切担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119474444","title":"Xenon制药提交Azetukalner新药申请至FDA用于局灶性癫痫，并更新精神科临床项目进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474444","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119474444?lang=zh_cn&edition=full","pubTime":"2026-09-18 04:02","pubTimestamp":1789675334,"startTime":"0","endTime":"0","summary":"Xenon制药正式宣布，已就其候选药物Azetukalner向美国食品药品监督管理局提交新药申请，该药物旨在治疗局灶性癫痫。与此同时，公司还对外披露了其精神科临床项目的最新动态。此次NDA提交标志着Azetukalner在监管审批道路上迈出了关键一步。作为一款备受瞩目的在研疗法，Azetukalner的申请递交获得了业界的广泛关注，为那些饱受局灶性癫痫困扰的患者群体带来了新的希望。不仅如此，Xenon制药还借此机会，就其正在推进的精神科适应症临床开发计划提供了补充说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571008?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BME","AZNH","IBB","IEHS","IE00B5TLWC47.USD","LU2473716301.USD","HELX","PSCH","LU2272731865.HKD","FBT","LU2272731782.SGD","BIOY","MRNY","IDNA","LU1992135399.USD","LU1992135472.HKD","BK4588","IYH","WDNA","RXL","GNOM","BK4585","LU2322448791.USD","MEDI","XBIX","IBRN","CANC","TMED","PJP","LU2322448957.HKD","BBH","SYNB","LFSC","PPH","LU2272731600.USD","MRNX","FTXH","RSPH","PBE","SBIO","IEIH","XPH","PBPH","BIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388058","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388058?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2089984988.USD","LU0310800379.SGD","LU2129689514.USD","GLAM","ABBV","IE000WAW04H5.SGD","LU2433249047.HKD","MYLD","PPH","LU0820561909.HKD","XLV","MEDX","FHLC","LU0859254822.USD","LU1267930490.SGD","LU2237443895.HKD","IXJ","LU0320765646.SGD","PJP","RXL","LU2087621335.USD","IE00B19Z3B42.SGD","LU0069063385.USD","AGNG","FTXH","LU1496350502.SGD","IYH","LU1839511570.USD","JDOC","LU0170899867.USD","LU0128525929.USD","BK4533","LU2129689605.HKD","LU0234570918.USD","LU2125909593.SGD","CALF","APGE","SBIO","TRUH","LU0124676726.USD","LU0114720955.EUR","LU0203345920.USD","VHT","LU1551013425.SGD","LU2237443549.SGD","XMMO","SG9999003800.SGD","IE0002141913.USD","LU1236620834.HKD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664053388?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z3581.USD","SG9999011175.SGD","LU1093756168.USD","LU0203345920.USD","FHLC","LU1934455194.USD","FTXH","CALF","LU0965509283.SGD","KCE","PJP","LU1236620834.HKD","GLAM","IE00B4R5TH58.HKD","IE00BLSP4239.USD","SBIO","IYH","AGNG","LU1003077747.HKD","BK4559","LU0057025933.USD","LU0124676726.USD","IE0004445239.USD","LU2237443549.SGD","IE0002270589.USD","LU1718418525.SGD","LU2089283258.USD","LU0170899867.USD","LU0256863902.USD","LU0985320562.USD","IE00B2B36J28.USD","MYLD","RXL","IE00BN8TJ469.HKD","LU1989772840.SGD","LU0289739343.SGD","JDOC","VHT","XLV","IXJ","PPH","XMMO","BK4581","APGE","LU1037948541.HKD","TRUH","ABBV","LU1983299246.USD","BK4566","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664521258?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BIOY","NVS","MRNY","FBT","IE00BFTCPJ56.SGD","LU0070302665.USD","HELX","PJP","XPH","IE00BJT1NW94.SGD","SYNB","RSPH","IE00B4R5TH58.HKD","MEDI","IBB","LFSC","LU2322448957.HKD","BME","IEIH","WDNA","IYH","AZNH","PBE","LU0211331839.USD","LU2473716301.USD","SBIO","BK4588","IE0009355771.USD","BK4007","BBP","RXL","CANC","MEDX","IDNA","IEHS","XBIX","BIB","TMED","PPH","LU2272731600.USD","BBH","FTXH","PSCH","GNOM","IBRN","IE00BJJMRZ35.SGD","PBPH","IE0002141913.USD","MRNX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663282078?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IPOS","ARTY","GDOC","IBB","AGIX","BIOY","QTOC","CHAT","VTHR","APXH","SBIO","GSKH","PBE","WRND","LFSC","XLVI","BBP","AIPO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044177?lang=zh_cn&edition=full","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","APXH","BIOY","BBP","GDOC","LFSC","PBE","SBIO","IBB","600513","WRND","BK0239","GSKH","XLVI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659504119?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1564","GDOC","LFSC","06881","BK0276","BK0188","SBIO","APXH","601881","XLVI","IBB","BK4588","BIOY","GSKH","PBE","BK1147","BBP","161027","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动：主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903675?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0102","PBE","BK4585","LFSC","BIOY","GSKH","SBIO","WRND","BK0216","BBP","IBB","BK4588","GDOC","XLVI","600721","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658692990?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WRND","PBE","SBIO","BIOY","XLVI","APXH","LFSC","BBP","GDOC","BK4588","BK4585","GSKH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658667990?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","PBE","SBIO","BIOY","XLVI","BK0102","APXH","LFSC","BBP","GDOC","BK4588","BK0216","BK4585","GSKH","600721","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alpsfunds.com/products/etf/SBIO","stockEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.1695},{"period":"6month","weight":0.0052},{"period":"1year","weight":0.2786},{"period":"ytd","weight":0.0896}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.001085},{"month":2,"riseRate":0.416667,"avgChangeRate":0.006941},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.031697},{"month":4,"riseRate":0.5,"avgChangeRate":0.010069},{"month":5,"riseRate":0.583333,"avgChangeRate":0.022132},{"month":6,"riseRate":0.666667,"avgChangeRate":0.043666},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025453},{"month":8,"riseRate":0.583333,"avgChangeRate":0.011469},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.02588},{"month":10,"riseRate":0.583333,"avgChangeRate":-0.00438},{"month":11,"riseRate":0.833333,"avgChangeRate":0.055086},{"month":12,"riseRate":0.454545,"avgChangeRate":0.000399}],"exchange":"ARCA","name":"ALPS Medical Breakthroughs ETF","nameEN":"ALPS Medical Breakthroughs ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ALPS Medical Breakthroughs ETF(SBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ALPS Medical Breakthroughs ETF,SBIO,ALPS Medical Breakthroughs ETF股票,ALPS Medical Breakthroughs ETF股票老虎,ALPS Medical Breakthroughs ETF股票老虎国际,ALPS Medical Breakthroughs ETF行情,ALPS Medical Breakthroughs ETF股票行情,ALPS Medical Breakthroughs ETF股价,ALPS Medical Breakthroughs ETF股市,ALPS Medical Breakthroughs ETF股票价格,ALPS Medical Breakthroughs ETF股票交易,ALPS Medical Breakthroughs ETF股票购买,ALPS Medical Breakthroughs ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ALPS Medical Breakthroughs ETF(SBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}